Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Astrocytoma 8Glioblastoma 5Recurrence 3Oligodendroglioma 2Neuroectodermal Tumors, Primitive 2Neurocytoma 2Glioma 2Brain Neoplasms 2Optic Nerve Glioma 1Neurofibroma 1Neuroblastoma 1Neurilemmoma 1Meningioma 1Gliosarcoma 1Ganglioglioma 1Diffuse Intrinsic Pontine Glioma 1Craniopharyngioma 1Central Nervous System Neoplasms 1

Interventions

Carboplatin 13Temozolomide 11Filgrastim 9Radiotherapy 6Etoposide 6Vincristine 5Irinotecan 4Granulocyte Colony-Stimulating Factor 4etoposide phosphate 3Peripheral Blood Stem Cell Transplantation 3O(6)-benzylguanine 3Ifosfamide 3Busulfan 3Vorinostat 2Topotecan 2Radiotherapy, Intensity-Modulated 2Psychiatric Rehabilitation 2Oxaliplatin 2Melphalan 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Doxorubicin 2Cyproheptadine 2Cyclophosphamide 2Cilengitide 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2veliparib 1trioctyl phosphine oxide 1tipifarnib 1sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Optic Nerve Glioma × antineoplaston AS 2-1 × CNS × Clear all
NCT01260103 2017-07-26

Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma

Burzynski Research Institute

Phase 3 Withdrawn
CNS

Recurrence, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡